CDLX vs. CRNC, API, DH, DOMO, HCAT, KLTR, GMGI, MTLS, HPAI, and ASUR
Should you be buying Cardlytics stock or one of its competitors? The main competitors of Cardlytics include Cerence (CRNC), Agora (API), Definitive Healthcare (DH), Domo (DOMO), Health Catalyst (HCAT), Kaltura (KLTR), Golden Matrix Group (GMGI), Materialise (MTLS), Helpport AI (HPAI), and Asure Software (ASUR). These companies are all part of the "computer software" industry.
Cardlytics vs.
Cerence (NASDAQ:CRNC) and Cardlytics (NASDAQ:CDLX) are both small-cap computer and technology companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation.
Cerence has a beta of 3.01, meaning that its stock price is 201% more volatile than the S&P 500. Comparatively, Cardlytics has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.
91.4% of Cerence shares are held by institutional investors. Comparatively, 68.1% of Cardlytics shares are held by institutional investors. 0.6% of Cerence shares are held by insiders. Comparatively, 4.4% of Cardlytics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Cardlytics received 135 more outperform votes than Cerence when rated by MarketBeat users. Likewise, 56.82% of users gave Cardlytics an outperform vote while only 54.88% of users gave Cerence an outperform vote.
Cardlytics has a net margin of -93.55% compared to Cerence's net margin of -260.68%. Cerence's return on equity of -8.66% beat Cardlytics' return on equity.
In the previous week, Cerence had 2 more articles in the media than Cardlytics. MarketBeat recorded 3 mentions for Cerence and 1 mentions for Cardlytics. Cardlytics' average media sentiment score of 1.87 beat Cerence's score of 1.10 indicating that Cardlytics is being referred to more favorably in the news media.
Cerence presently has a consensus price target of $8.60, suggesting a potential upside of 13.71%. Cardlytics has a consensus price target of $6.42, suggesting a potential upside of 341.01%. Given Cardlytics' stronger consensus rating and higher possible upside, analysts plainly believe Cardlytics is more favorable than Cerence.
Cardlytics has higher revenue and earnings than Cerence. Cerence is trading at a lower price-to-earnings ratio than Cardlytics, indicating that it is currently the more affordable of the two stocks.
Summary
Cardlytics beats Cerence on 12 of the 19 factors compared between the two stocks.
Get Cardlytics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDLX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardlytics Competitors List
Related Companies and Tools
This page (NASDAQ:CDLX) was last updated on 4/15/2025 by MarketBeat.com Staff
Buy CDLX Stock Free CDLX Stock Alerts